Navigation Links
ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma

STRIBUTION PROGRAM. THIS PROGRAM IS CALLED "RevAssist(R)". UNDER THIS PROGRAM, ONLY PRESCRIBERS AND PHARMACISTS REGISTERED WITH THE PROGRAM CAN PRESCRIBE AND DISPENSE THE PRODUCT. IN ADDITION, REVLIMID(R) (lenalidomide) MUST ONLY BE DISPENSED TO PATIENTS WHO ARE REGISTERED AND MEET ALL THE CONDITIONS OF THE RevAssist(R) PROGRAM.

2. HEMATOLOGIC TOXICITY (NEUTROPENIA AND THROMBOCYTOPENIA).

THIS DRUG IS ASSOCIATED WITH SIGNIFICANT NEUTROPENIA AND THROMBOCYTOPENIA. EIGHTY PERCENT OF PATIENTS WITH DEL 5q MYELODYSPLASTIC SYNDROMES HAD TO HAVE A DOSE DELAY/REDUCTION DURING THE MAJOR STUDY. THIRTY-FOUR PERCENT OF PATIENTS HAD TO HAVE A SECOND DOSE DELAY/REDUCTION. GRADE 3 OR 4 HEMATOLOGIC TOXICITY WAS SEEN IN 80% OF PATIENTS ENROLLED IN THE STUDY. PATIENTS ON THERAPY FOR DEL 5q MYELODYSPLASTIC SYNDROMES SHOULD HAVE THEIR COMPLETE BLOOD COUNTS MONITORED WEEKLY FOR THE FIRST 8 WEEKS OF THERAPY AND AT LEAST MONTHLY THEREAFTER. PATIENTS MAY REQUIRE DOSE INTERRUPTION AND/OR REDUCTION. PATIENTS MAY REQUIRE USE OF BLOOD PRODUCT SUPPORT AND/OR GROWTH FACTORS. (SEE DOSAGE AND ADMINISTRATION)

3. DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM.

This drug has demonstrated a significantly increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple myeloma who were treated with REVLIMID(R) (lenalidomide) combination therapy. Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. It is not known whether prophylactic anticoagulation or antiplatelet therapy prescribed in conjunction with REVLIMID(R) (lenalidomide) may lessen the potential for venous thromboembolic events. The decision to take prophylactic measures should be done carefully after an assessment of an individual patient's underlying risk factors.

You can get information abo
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
(Date:7/10/2014)... July 10, 2014  Decision Resources Group finds ... disease (ID) specialists are willing to prescribe Durata,s ... for use as OPAT, approximately two-thirds of the ... to their hospital inpatients. However, our findings indicate ... are initiated on OPAT following hospital discharge, and ...
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
(Date:7/11/2014)... New York, NY (PRWEB) July 11, 2014 ... ( http://www.gynecaremorcellatorlawsuit.com/ ) investigation, Bernstein Liebhard LLP has ... U.S. Food & Drug Administration’s (FDA) Obstetrics ... to explore ways to mitigate the cancer risks ... minimally invasive gynecological surgeries. According to a report ...
(Date:7/11/2014)... Datalogic brings a new and innovative scanner ... With their new Gryphon GD4400 and GM4400 ... devastating MRSA, which claimed 5,500 lives, becomes more preventable. ... and the Gryphon GM4400-HC 2D readers can scan nearly ... barcodes off of troublesome LCD monitors, smartphones, and other ...
(Date:7/11/2014)... -- In people with sex addiction, pornography affects the ... in drug addicts as they consume drugs, a new ... activity between patients who have compulsive sexual behavior and ... study author Dr. Valerie Voon, of the University of ... Voon,s research involved 19 men with sex addiction ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... comes to the summer concert schedule, it just isn’t complete without ... of the biggest names in country music and one of the ... his “That’s My Kind of Night” tour featuring Lee Brice and ... through the rest of the summer and into the fall includes ...
(Date:7/11/2014)... July 11, 2014 According to a ... Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, ... Industrial, Automotive & Transportation, Agriculture) & Geography - Global ... of Internet of Things market was worth $1029.5 Billion ... by 2020, at an estimated CAGR of 4.08% from ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4
... physicians taking part in the Physicians' Health Study, those ... cereals reduced their risk of heart failure by 22 ... at the American Heart Association's 47th Annual Conference on ... strong body of evidence linking the consumption of wholegrain ...
... It's already been established that type 2 diabetes increases the ... also a link between type 1 diabetes and this type ... but still, those with type 1 diabetes have a likelihood ... in non-diabetics. This is similar to the risk those with ...
... panic disorder and other mental health conditions are potentially around ... study. ,The findings, which were based on analysis ... March 6 in the American Journal of Medical Genetics. ... a quantum leap in psychiatry,' said the study's lead author, ...
... has said that India, home to 12 million blind people, ... 2015, five years before the World Health Organisation (WHO) deadline ... a little above 1.1 percent. And looking at the progress ... We are quite sure that the WHO target of 0.3 ...
... team led by a University of Leicester geologist was recently ... to detect exposure of UK troops to depleted uranium (DU) ... ,Randall Parrish, Professor of Isotope Geology, developed the test with ... University of Frankfurt, Germany, and his colleague Matt Horstwood at ...
... Studying the genetic make-up using blood samples to detect ... been in practice//. Now, scientists have gone a bit ... tests that might reveal the latent tendencies in people ... personality disorder. ,Such tests would not dictate ...
Cached Medicine News:Health News:Whole Grain Breakfasts Linked to Lower Heart Failure Risk 2Health News:Blood Tests may Be Possible for Mental Health Conditions 2Health News:DU Test Finds UK Troops Uranium Free 2Health News:Genetic Tests to Reveal ‘substance Abuse’ Tendenci 2Health News:Genetic Tests to Reveal ‘substance Abuse’ Tendenci 3
Curved shafts with micro Pierse type tips. Flat open serrated handle with dull finish....
Straight shafts with 0.1 mm Pierse tips. Flat smooth handle with dull finish....
Colibri style 0.1 mm Pierse tips. Flat smooth handle with dull finish....
The Elschnig teeth of this forceps are ideal for grasping sclera during suturing. Delicate tying platform handles the finest suture material. 0.12 mm, 1 x 2 teeth....
Medicine Products: